Docket No.: 50229-436 **PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Customer Number: 20277

Craig JORDAN : Confirmation Number:

Serial No.: Continuation of Appl. No.

09/799,100 : Group Art Unit:

Filed: April 23, 2004 : Examiner:

For: METHODS TO IMPAIR HEMATOLOGIC CANCER PROGENITOR CELLS AND

COMPOUNDS RELATED THERETO

INFORMATION DISCLOSURE STATEMENT

Mail Stop Information Disclosure Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached form PTO-1449. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

The references were cited by or submitted to the U.S. Patent and Trademark Office in parent application Serial No. <u>09/799,100</u>, filed <u>March 6, 2001</u>, which is relied upon for an earlier

Serial No.: Continuation of Appl. No.

filing date under 35 USC 120. Thus, copies of these references are not attached. 37 CFR 1.98(d).

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.

Respectfully submitted,

MCDERMOTT, WILL & EMERY

Kelli N. Watson

Registration No. 47,170

600 13th Street, N.W. Washington, DC 20005-3096 (202) 756-8000 KNW:prg

Facsimile: (202) 756-8087

Date: April 23, 2004

| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | | | | | | ATTY. DOCKET NO. 50229-436 | SERIAL NO. Continuation of Appl. No. 09/799,100 | | | | | |
|--|--|--|---|---------------------------------|-----------|---|---|----------|---|-------------|-----------|--|
| | | | | | | APPLICANT Craig JORDAN | | | | | | |
| (PTO-1449) | | | | | | FILING DATE GF April 23, 2004 | | | ROUP | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | |
| EXAMINER'S INITIALS | CITE NO. | Num | Document Number ber-Kind Code2 (# known) | Publication Dat MM-DD-YYYY | | Name of Patentee or Applicant of Cite Document | | | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | | | |
| | | US | 5,489,516 | 02/06/1996 | | Broudy et al. | | | | | | |
| | | US | | | | | | | | | | |
| | ļ | US | | | | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | |
| EXAMINER'S | | Foreign Patent Document Country Codes -Number 4 -Kind Codes (if known) | | Publication Date MM-DD-YYYY | | Name of Patentee or | Pages, Columns, Lines Where Relevant Figures Appear | | | Translation | | |
| INITIALS | CITE NO. | | | | | Applicant of Cited Document | | | Yes No | | | |
| | | | WO 97 24373 A | 07/10/1997 | \dagger | MEDVET SCIENCY PYT. LTD. | | | - | | 110 | |
| · · · · · · · · · · · · · · · · · · · | | | | | + | | | | | | | |
| | | | | | | | | | _ | | | |
| | | | | | _ | | | | | | | |
| | L | i | OTHERA | Title, Date, Pertinent Pages, E | to \ | | | | | | | |
| EXAMINER'S | | Inclu | | , - | | | • | e of the | item (bo | ok magazin | <u> </u> | |
| INITIALS | CITE NO. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | | | | | | | | |
| | | Q. Sun et al.: "Monoclonal antibody 7G3 Recognizes the <i>N</i> -Terminal Domain of the Human Interleukin-3 (IL-3) Receptor Alpha-Chain and Functions as a Specific IL-3 receptor Antagonist." <u>Blood</u> , vol. 87, no. 1, 1 January 1996 (1996-01-01), pages 83-92, XP002105606. | | | | | | | | | | |
| | | Mye | C. Jordan et al.: "The Interleukin-3 Receptor alpha Chain is Highly Expressed On Primitive Acute Myelogenous Leukemia." <u>Blood</u> , vol. 94, no. 10 suppl. 1 (part 1 of 2), 15 November 1999 (1999-11-15), page 67a XP002174823. | | | | | | | | | |
| | | C. Chan et al.: "Reactivity of Murine Cytokine Fusion Toxin, Diphteria Toxin390-Murine Interleukin-3 (DT-390-Mil-3), With Bone Marrow Progrenitor Cells." <u>Blood</u> , vol. 88, no. 4, 15 August 1996 (1996-08-15), pages 1445-1456, XP000611395. | | | | | | | | | es | |
| | K. Koubek et al.: "Occurrence of Cytokine Receptors On Different Lymphoid Leukaemic Cells." European Journal of Haematology, vol. 63, no. 1, July 1999 (1999-07), pages 1-10, XP001015741. | | | | | | | | | | | |
| D. Tweardy et al.: "Modulation of Myeloid Proliferation And Differentiation By Monoclonal Antibodies Directed Against A Protein That Interacts With The Interleukin-3 Receptor." <u>Blood</u> , vol. 80, no. 2, 15 July 1992 (1992-07-15), pages 359-366, XP001015735. | | | | | | | | | | | ted 2- | |
| EXAMINER | | | | | | | DATE CO | NSIDE | RED | | | |
| | | | | | | | | | | | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.